Notícias Aptose Biosciences Inc - APS | Ações Toronto Stock Exchange | ADVFN Brasil

Índice Bovespa

US Dollar vs BRL

Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.

Cadastre-se

Início
Investir
Ações
Canadá
TSX
Aptose Biosciences Inc (APS)
Aptose Biosciences Inc (APS) Notícias

Aptose Biosciences Inc (APS)

0,27

-0,07

(-20,59%)

Fechado 23 Novembro 6:12PM

Atrasado por 15 minutos

Capacite seu portfólio: Discussões em tempo real e ideias de negociação acionáveis.

Aptose Biosciences Inc. Announces Pricing of $8 Million Public Offering

Aptose Initiates TUSCANY Phase 1/2 Study for Newly Diagnosed AML Patients to Receive Tuspetinib-based Triplet Therapy

Aptose Reports Results for the Third Quarter 2024

Aptose Announces Results from Special Meeting of Shareholders

Aptose Receives $10 Million Through a Facility Agreement with Hanmi; Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop Tuspetinib

Aptose Announces Adjournment of its Special Meeting of Shareholders

Aptose Reports Results for the Second Quarter 2024

Aptose Announces Receipt of Deficiency Notice from Nasdaq

Aptose Biosciences to Present at the 19th Annual Rodman & Renshaw Global Investment Conference

Aptose Reports Results for the Second Quarter Ended June 30, 2017

Aptose Biosciences to Present at Canaccord Genuity 37th Annual Growth Conference

Aptose To Release Second Quarter Ended June 30, 2017 Financial Results and Hold Conference Call on August 8, 2017

Aptose Biosciences Announces Results of Annual Meeting of Shareholders

Aptose Reports Results for the First Quarter Ended March 31, 2017

Preclinical Data on Aptose Biosciences FLT3/BTK Inhibitor CG’806 Presented at AACR Hematologic Malignancies Meeting

Fóruns

Nenhuma Discussão Encontrada

Criar Nova Discussão

Aptose Biosciences

Delayed Upgrade Clock

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições